Parkinson disease (PD) is a complex disorder with motor, cognitive, and behavioral dysfunctions that change over time. The methods to study PD have also become ijiore complex, including the study of biomarkers, genetics, and postmortem-dependent neurobiology. Thus, a successful Clinical Core must not only characterize the motor, cognitive, and behavioral function in PD subjects over time, but also concomitantly carefully collect biological fluids during that same timeframe, and obtain postmortem material from these well-characterized subjects. The primary goal of the Clinical Core will be to support the Pacific Northwest Udall Center (PANUC) Projects through longitudinal characterization of PD subjects and generation of biologic samples from these subjects. To accomplish this goal two PD subject samples will be established. The """"""""community"""""""" sample (CS) will be a larger sample evaluated by Clinical Core study personnel at local movement disorder clinics, or at their homes, twice during the five year Center funding cycle. This sample will generate the large number of blood samples, with clinical characterization, needed for the biomarker and genetic projects. The CS will also be the source of subjects for the """"""""annual"""""""" sample (AS). The AS will be a smaller subject sample selected for clinical characteristics on screening (e.g., cognitive subtypes such as cognitive impairment without dementia). AS subjects will be evaluated annually at the study site and will have more detailed clinical characterization. In addition, these subjects will be recruited for lumbar punctures to supply CSF for biomarker studies, and for autopsy. The Clinical Core will, therefore, develop PD subject samples with detailed clinical characterization, and collect biological samples from the subjects, to support Projects 2 and 3 in PANUC as well as closely aligned studies. Clinical data, DNA, and biofluids from control individuals will be obtained through the same protocols at each sites'respective NIH-funded AD Center. These unique and integrated data and samples from longitudinally evaluated PD subjects will be an invaluable resource for future studies by PANUC investigators, and for other investigators from within and outside the participating institutions.

Public Health Relevance

Parkinson's Disease (PD) is a progressive disease of the brain that currently affects over a million Americans. We now know that in addition to the movement problems commonly associated with PD this disease eventually also affects a persons thinking or cognitive abilities. This study will improve our understanding of what causes PD-associated cognitive decline, with the long-term objective of developing better treatments for this disabling facet of PD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS062684-04
Application #
8382343
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
4
Fiscal Year
2012
Total Cost
$640,722
Indirect Cost
$78,188
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Boord, Peter; Madhyastha, Tara M; Askren, Mary K et al. (2017) Executive attention networks show altered relationship with default mode network in PD. Neuroimage Clin 13:1-8
Hendershott, Taylor R; Zhu, Delphine; Llanes, Seoni et al. (2017) Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson's disease. Parkinsonism Relat Disord 38:31-34
Cooper, Christine A; Jain, Nimansha; Gallagher, Michael D et al. (2017) Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. Ann Clin Transl Neurol 4:15-25
Wile, Daryl J; Agarwal, Pankaj A; Schulzer, Michael et al. (2017) Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurol 16:351-359
Irwin, David J; Grossman, Murray; Weintraub, Daniel et al. (2017) Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 16:55-65
Corces, M Ryan; Trevino, Alexandro E; Hamilton, Emily G et al. (2017) An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat Methods 14:959-962
Cholerton, Brenna; Omidpanah, Adam; Madhyastha, Tara M et al. (2017) Total Brain and Hippocampal Volumes and Cognition in Older American Indians: The Strong Heart Study. Alzheimer Dis Assoc Disord 31:94-100
Gatto, Emilia M; Allegri, Ricardo F; Da Prat, Gustavo et al. (2017) Intrafamilial variable phenotype including corticobasal syndrome in a family with p.P301L mutation in the MAPT gene: first report in South America. Neurobiol Aging 53:195.e11-195.e17
Hill-Burns, Erin M; Debelius, Justine W; Morton, James T et al. (2017) Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov Disord 32:739-749
Postupna, Nadia; Latimer, Caitlin S; Larson, Eric B et al. (2017) Human Striatal Dopaminergic and Regional Serotonergic Synaptic Degeneration with Lewy Body Disease and Inheritance of APOE ?4. Am J Pathol 187:884-895

Showing the most recent 10 out of 165 publications